FDA Approves Eli Lilly's Tirzepatide for Weight Loss, Revolutionizing Obesity Treatment

The FDA has approved Eli Lilly's drug tirzepatide for weight loss, expanding its use beyond the treatment of Type 2 diabetes. Marketed as Zepbound, the drug can now be used by adults who are overweight or have obesity with at least one weight-related condition for chronic weight management. Prior to this approval, tirzepatide was often used off-label for weight loss, along with other drugs like Wegovy and Ozempic. The approval solidifies Eli Lilly's position in the obesity drug market, which analysts predict could reach $100 billion by 2030. Obesity affects a significant portion of the global population, and the approval addresses an unmet medical need. Tirzepatide works by activating two hormones in the body that suppress appetite and make people feel full for longer.